Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
1726 nm Lasers for the Treatment of Acne Vulgaris
Skin Therapy Lett. 2024 Jan;29(1):5-7.ABSTRACTThe treatment of acne vulgaris traditionally consists of a combination of topical and oral medications. The use of lasers to treat this condition has been an area of increasing research, and several types have previously been used in the treatment of acne. New 1726 nm lasers specifically target the sebaceous gland, which is known to be pivotal in acne pathophysiology. This laser wavelength demonstrates substantial potential as a safe and effective therapeutic option for moderate to severe acne without the risks of systemic therapy. This paper reviews the 1726 nm lasers for acne...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Julie Bittar Perry Hooper Jeffrey S Dover Source Type: research
Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients
Skin Therapy Lett. 2024 Jan;29(1):1-4.ABSTRACTGeneralized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flare...
Source: Skin Therapy Letter - January 25, 2024 Category: Dermatology Authors: Tuba Bukhari Mariya Markovina Abrahim Abduelmula Brian D Rankin Ronald Vender Jensen Yeung Alim R Devani Vimal H Prajapati Source Type: research
